Development of radioiodine-labeled mequitazine for evaluation of hepatic CYP2D activity.
Mizutani A, Kobayashi M, Nishi K, Fujita KI, Takahashi K, Muranaka Y, Sato K, Kitamura M, Suzuki C, Nishii R, Shikano N, Magata Y, Ishida Y, Kunishima M, Fukuchi K, Kawai K.
Mizutani A, et al. Among authors: fukuchi k.
Front Pharmacol. 2024 Jun 19;15:1397288. doi: 10.3389/fphar.2024.1397288. eCollection 2024.
Front Pharmacol. 2024.
PMID: 38962307
Free PMC article.